ATE549412T1 - Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon - Google Patents

Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon

Info

Publication number
ATE549412T1
ATE549412T1 AT99915272T AT99915272T ATE549412T1 AT E549412 T1 ATE549412 T1 AT E549412T1 AT 99915272 T AT99915272 T AT 99915272T AT 99915272 T AT99915272 T AT 99915272T AT E549412 T1 ATE549412 T1 AT E549412T1
Authority
AT
Austria
Prior art keywords
fluorophenyl
formula
compound
hydroxy
medium
Prior art date
Application number
AT99915272T
Other languages
English (en)
Inventor
Michael Homann
Edward Previte
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE549412T1 publication Critical patent/ATE549412T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99915272T 1999-04-05 1999-04-05 Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon ATE549412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/007445 WO2000060107A1 (en) 1999-04-05 1999-04-05 Stereoselective microbial reduction for the preparation of 1 - (4-fluorophenyl) - 3(r)-[3(s) - hydroxy-3 - (4-fluorophenyl) propyl)]-4(s) - (4-hydroxyphenyl)-2-azetidinone

Publications (1)

Publication Number Publication Date
ATE549412T1 true ATE549412T1 (de) 2012-03-15

Family

ID=22272502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915272T ATE549412T1 (de) 1999-04-05 1999-04-05 Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon

Country Status (8)

Country Link
EP (2) EP2281899A3 (de)
JP (1) JP3679715B2 (de)
CN (1) CN1249250C (de)
AT (1) ATE549412T1 (de)
AU (1) AU3382699A (de)
CA (1) CA2367289C (de)
HK (1) HK1042115A1 (de)
WO (1) WO2000060107A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EE05453B1 (et) 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1601668B1 (de) 2003-03-07 2008-08-27 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1699759B1 (de) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1986489A2 (de) 2006-02-24 2008-11-05 Schering Corporation Npc1l1-orthologe
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EA017349B1 (ru) 2007-01-24 2012-11-30 Крка Способ получения эзетимиба и его производных
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
EP2414529A2 (de) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatisches verfahren zur herstellung von (s)-5-(4-fluorphenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-on, einer zwischenstufe von ezetimib, und weitere umwandlung zu ezetimib
WO2011140219A1 (en) 2010-05-04 2011-11-10 Codexis, Inc. Biocatalysts for ezetimibe synthesis
CN118792173B (zh) * 2024-09-11 2025-01-24 黑龙江大学 一株产五味子醇甲的五味子内生真菌wwzz01及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61141894A (ja) * 1984-12-17 1986-06-28 Sankyo Co Ltd β−ラクタム化合物の製法
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon

Also Published As

Publication number Publication date
EP1169468A1 (de) 2002-01-09
WO2000060107A1 (en) 2000-10-12
CN1344329A (zh) 2002-04-10
CN1249250C (zh) 2006-04-05
CA2367289A1 (en) 2000-10-12
AU3382699A (en) 2000-10-23
EP1169468B1 (de) 2012-03-14
JP3679715B2 (ja) 2005-08-03
EP2281899A2 (de) 2011-02-09
CA2367289C (en) 2008-02-12
EP2281899A3 (de) 2012-01-04
JP2002540797A (ja) 2002-12-03
HK1042115A1 (zh) 2002-08-02

Similar Documents

Publication Publication Date Title
ATE549412T1 (de) Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
AU6252599A (en) Resolution of trans-2 -(alkoxycarbonylethyl) -lactams useful in the synthesis of 1- (4-fluorophenyl) -3(r) -(3(s) -hydroxy-3 -(4-fluorophenyl) -propyl)) -4(s) (4-hydroxyphenyl) -2-azetidinone
ATE93520T1 (de) Verfahren zur herstellung von optisch aktiven acyloxyazetidinonen.
DE69917061T2 (de) Nitrocumarine für den nachweis aller mikroorganismen
Liang et al. Chemoenzymatic synthesis of isogalactofagomine
DK0781345T3 (da) Fremgangsmåde til opnåelse af vanillinsyre og vanillin ved biokonversion med en kombination af filamentøse mikroorganismer
AU3222195A (en) Organic compounds
EP0855446A3 (de) Verfahren zur Herstellung von optisch aktiven Azetidin-2-Carbonsäurederivaten
AU3354095A (en) Process for producing alkoxyiminoacetamide derivative
DK0839211T3 (da) Fremgangsmåde til fremstilling af riboflavin ved hjælp af mikroorganismer med ændret isocitratlyaseaktivitet
DE69626128D1 (de) Stereoselektiver, mikrobieller reduktionsprozess
Adam et al. Preparation of optically active allylic hydroperoxy alcohols and 1, 3-diols by enzyme-catalyzed kinetic resolution and photooxygenation of chiral homoallylic alcohols
EP0848065A3 (de) Verfahren zur Verbesserung der optischen Reinheit einer Amin-Verbindung
AU5209600A (en) Orally active androgens
NO20054456L (no) Fremgangsmate for fremstilling av enantiomere former av cis-konfigurerte 1,3-cykloheksandiolderivater
BG103704A (en) New compounds
DE69031730D1 (de) Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
DE60216616D1 (de) Enzymatisches verfahren zur herstellung von organofluorverbindungen
EP1283200A3 (de) Optisch reine Zwischenstoffe der Paroxetin
KR940019681A (ko) 베타-락탐 화합물의 제조방법 및 그의 중간체
WO2000039324A3 (de) Verfahren zur herstellung von optisch aktiven 1- amino-4- (hydroxymethyl)- cyclopent-2- en-derivaten
AU5416600A (en) Process for the preparation of fumagillin
RU94003612A (ru) Способ производства водки
DE69620170D1 (de) Herstellung von hydroxyverbindungen durch biokonversion mit dioxygenase
ATE244228T1 (de) Verfahren zur herstellung von chloroacetylaminothiazoleaceticsäure derivate